[go: up one dir, main page]

MX2017008875A - Anticuerpos biespecificos contra cd3 y cd20. - Google Patents

Anticuerpos biespecificos contra cd3 y cd20.

Info

Publication number
MX2017008875A
MX2017008875A MX2017008875A MX2017008875A MX2017008875A MX 2017008875 A MX2017008875 A MX 2017008875A MX 2017008875 A MX2017008875 A MX 2017008875A MX 2017008875 A MX2017008875 A MX 2017008875A MX 2017008875 A MX2017008875 A MX 2017008875A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
antibodies against
diseases
cell
treatment
Prior art date
Application number
MX2017008875A
Other languages
English (en)
Other versions
MX391279B (es
Inventor
Schuurman Janine
Parren Paul
Verploegen Sandra
Breij Esther
Satijn David
ENGELBERTS Patrick
Rademaker Rik
Altintas Isil
VAN DIJKHUIZEN RADERSMA Riemke
Van Den Brink Edward
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56355550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017008875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2015/050276 external-priority patent/WO2015104346A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of MX2017008875A publication Critical patent/MX2017008875A/es
Publication of MX391279B publication Critical patent/MX391279B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Se describen anticuerpos biespecíficos dirigidos a CD3 y CD20 y usos de tales anticuerpos biespecíficos, en particular uso de los mismos en el tratamiento de enfermedades en las cuales el direccionado específico y eliminación mediada por célula T de células que expresan CD20 se desean.
MX2017008875A 2015-01-08 2016-01-08 Anticuerpos biespecíficos contra cd3 y cd20. MX391279B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/EP2015/050276 WO2015104346A1 (en) 2014-01-09 2015-01-08 Humanized or chimeric cd3 antibodies
DKPA201500412 2015-07-15
DKPA201500413 2015-07-15
DKPA201500416 2015-07-16
DKPA201500415 2015-07-16
PCT/EP2016/050296 WO2016110576A1 (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20

Publications (2)

Publication Number Publication Date
MX2017008875A true MX2017008875A (es) 2017-09-27
MX391279B MX391279B (es) 2025-03-21

Family

ID=56355550

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008875A MX391279B (es) 2015-01-08 2016-01-08 Anticuerpos biespecíficos contra cd3 y cd20.
MX2022004082A MX2022004082A (es) 2015-01-08 2017-07-04 Anticuerpos biespecificos contra cd3 y cd20.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004082A MX2022004082A (es) 2015-01-08 2017-07-04 Anticuerpos biespecificos contra cd3 y cd20.

Country Status (13)

Country Link
US (2) US10544220B2 (es)
EP (1) EP3242682A1 (es)
JP (3) JP6853176B2 (es)
KR (3) KR102663073B1 (es)
CN (2) CN107660214B (es)
AU (2) AU2016205967B2 (es)
CA (1) CA2973159A1 (es)
EA (1) EA201791554A1 (es)
IL (3) IL318350A (es)
MX (2) MX391279B (es)
SG (1) SG11201705496SA (es)
UA (1) UA120286C2 (es)
WO (1) WO2016110576A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6514103B2 (ja) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
KR20250078622A (ko) * 2013-07-05 2025-06-02 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
PE20210648A1 (es) 2013-12-17 2021-03-26 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
MX2017003022A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados.
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック， インコーポレイテッド 抗ｃｌｌ－１抗体及び使用方法
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
HRP20231134T1 (hr) 2015-06-16 2024-01-05 F. Hoffmann - La Roche Ag Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
JP2018526981A (ja) 2015-07-15 2018-09-20 ゲンマブ エー／エス ヒト化またはキメラｃｄ３抗体
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3252078A1 (en) * 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3519823B1 (fr) * 2016-09-30 2021-05-12 Centre National De La Recherche Scientifique Marqueurs membranaires
KR20190074300A (ko) * 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
MX2019006954A (es) * 2016-12-20 2019-08-01 Hoffmann La Roche Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
KR20200014304A (ko) * 2017-06-02 2020-02-10 에프. 호프만-라 로슈 아게 암의 치료를 위한 제ii형 항-cd20 항체 및 항-cd20/항-cd3 이중특이적 항체
CN111356477B (zh) 2017-08-01 2024-08-30 Ab工作室有限公司 双特异性抗体及其用途
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
EP3668898B1 (en) 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
CN107501412A (zh) * 2017-10-11 2017-12-22 深圳精准医疗科技有限公司 突变型双特异性抗体及其应用
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
KR20200119275A (ko) * 2018-02-09 2020-10-19 젠맵 에이/에스 Cd3 및 cd20에 대해 지정된 이중특이적 항체를 포함하는 제약 조성물 및 그의 용도
JP7377590B2 (ja) * 2018-03-14 2023-11-10 ノビミューン エスアー 抗ｃｄ３イプシロン抗体およびそれを使用する方法
EP3569617A1 (en) * 2018-05-18 2019-11-20 Trion Research GmbH Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109836502B (zh) * 2018-11-12 2021-09-07 浙江大学 一种双特异性抗体及其应用
CN116178547A (zh) * 2019-02-22 2023-05-30 武汉友芝友生物制药股份有限公司 Cd3抗原结合片段及其应用
JP7273195B2 (ja) * 2019-05-13 2023-05-12 エフ． ホフマン－ラ ロシュ アーゲー 干渉抑制薬物動態イムノアッセイ
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
CA3149333A1 (en) * 2019-08-15 2021-02-18 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
CN111100204B (zh) * 2019-11-26 2022-03-11 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
KR20220113790A (ko) 2019-12-13 2022-08-16 제넨테크, 인크. 항-ly6g6d 항체 및 사용 방법
JP2023509991A (ja) * 2020-01-13 2023-03-10 シンアフィックス ビー．ブイ． 抗体及び免疫細胞エンゲージャーのコンジュゲート
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
EP4121456A1 (en) * 2020-03-18 2023-01-25 Genmab A/S Antibodies binding to b7h4
BR112022022730A2 (pt) 2020-05-08 2023-02-14 Genmab As Método para tratar um linfoma não hodgkin de células b em um indivíduo humano
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
MX2023002541A (es) * 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes.
US20230355753A1 (en) 2020-09-10 2023-11-09 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CA3192251A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CA3190376A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
WO2022053653A1 (en) * 2020-09-10 2022-03-17 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
KR20230066391A (ko) * 2020-09-10 2023-05-15 젠맵 에이/에스 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
AU2021374592A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
EP4304616A4 (en) * 2021-03-10 2025-02-26 H. Lee Moffitt Cancer Center & Research Institute, Inc. COMPOSITIONS AND METHODS FOR REDUCING THE TOXICITY OF THERAPEUTIC T CELLS
CN116964085A (zh) * 2021-03-12 2023-10-27 根马布股份公司 非激活抗体变体
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
IL308417A (en) 2021-05-14 2024-01-01 Genentech Inc Methods for the treatment of CD20-positive proliferative disorder with musuntozumab and folatuzumab and dotin
US20250101102A1 (en) 2022-01-28 2025-03-27 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20230241211A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2025512377A (ja) 2022-04-11 2025-04-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ユニバーサルな腫瘍細胞殺傷のための組成物及び方法
JP7579481B2 (ja) 2022-04-13 2024-11-07 ジェネンテック， インコーポレイテッド モスネツズマブの医薬組成物および使用方法
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
AU2023398887A1 (en) * 2022-12-14 2025-06-26 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
WO2024206884A1 (en) 2023-03-31 2024-10-03 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
WO2024213754A1 (en) 2023-04-13 2024-10-17 Genmab A/S Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
WO2024236035A1 (en) 2023-05-15 2024-11-21 Genmab A/S Methods of treating cd20 expressing b-cell cancers
TW202509073A (zh) 2023-05-15 2025-03-01 丹麥商珍美寶股份有限公司 高度純化之依可利單抗組成物
WO2025064890A1 (en) * 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025109119A1 (en) * 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1729203B (zh) * 2002-10-17 2014-02-19 根马布股份公司 抗cd20的人单克隆抗体
EP3178850B1 (en) * 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
AU2008255350B2 (en) * 2007-05-31 2014-07-10 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
AU2008255387B2 (en) * 2007-05-31 2014-06-26 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
EP2155790A1 (en) * 2007-05-31 2010-02-24 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
WO2010037838A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN105693861A (zh) 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
NZ701825A (en) * 2010-04-20 2016-06-24 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
KR20220082104A (ko) * 2010-11-30 2022-06-16 추가이 세이야쿠 가부시키가이샤 세포상해 유도 치료제
CN103796677B (zh) * 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
SG195072A1 (en) * 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
ES2659764T3 (es) 2011-08-23 2018-03-19 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de linfocitos T
JP6514103B2 (ja) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CA2896370A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
KR20250078622A (ko) 2013-07-05 2025-06-02 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
AU2014287011A1 (en) * 2013-07-12 2016-02-25 Zymeworks Inc. Bispecific CD3 and CD19 antigen binding constructs
PE20210648A1 (es) * 2013-12-17 2021-03-26 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
WO2017210485A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
EP3668898B1 (en) * 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
KR20230066391A (ko) * 2020-09-10 2023-05-15 젠맵 에이/에스 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체

Also Published As

Publication number Publication date
IL289946A (en) 2022-03-01
BR112017014551A2 (pt) 2018-05-15
CN107660214A (zh) 2018-02-02
MX2022004082A (es) 2022-05-03
AU2016205967A1 (en) 2017-07-27
AU2016205967B2 (en) 2021-11-11
MX391279B (es) 2025-03-21
JP7596342B2 (ja) 2024-12-09
IL289946B2 (en) 2025-06-01
IL318350A (en) 2025-03-01
AU2022200871A1 (en) 2022-03-03
KR102712786B1 (ko) 2024-10-04
KR20240148942A (ko) 2024-10-11
US20170355767A1 (en) 2017-12-14
CN107660214B (zh) 2022-02-08
SG11201705496SA (en) 2017-08-30
JP7177317B2 (ja) 2022-11-24
IL289946B1 (en) 2025-02-01
US10544220B2 (en) 2020-01-28
JP2018508188A (ja) 2018-03-29
UA120286C2 (uk) 2019-11-11
JP2021104020A (ja) 2021-07-26
CN114478792A (zh) 2022-05-13
JP6853176B2 (ja) 2021-03-31
NZ733531A (en) 2024-11-29
KR20240064746A (ko) 2024-05-13
KR102663073B1 (ko) 2024-05-07
CA2973159A1 (en) 2016-07-14
EA201791554A1 (ru) 2017-12-29
EP3242682A1 (en) 2017-11-15
KR20170128222A (ko) 2017-11-22
WO2016110576A1 (en) 2016-07-14
US20200199231A1 (en) 2020-06-25
AU2022200871B2 (en) 2025-05-08
IL253166B (en) 2022-02-01
IL253166A0 (en) 2017-08-31
JP2023002615A (ja) 2023-01-10

Similar Documents

Publication Publication Date Title
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
ECSP18011248A (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
CL2017001736A1 (es) Anticuerpos anti-cd47 y uso de los mismos.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
CL2018000819A1 (es) Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
GT201700188A (es) Anticuerpos contra tau y sus usos
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
PE20181005A1 (es) Anticuerpos biespecificos contra el a- beta humano y el receptor de transferrina humano y metodos de uso
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
MX387463B (es) Moléculas de unión a antígeno biespecíficas activadoras de células t y antagonistas de unión al eje de pd-1 y usos de los mismos para el tratamiento de cáncer.
MX381724B (es) Cadenas ligeras comunes y metodos de uso.
CR20170109A (es) Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
CO2017005404A2 (es) Anticuerpos contra il-6